Pharvaris (PHVS) Projected to Post Earnings on Wednesday

Pharvaris (NASDAQ:PHVS) is projected to post its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Pharvaris to post earnings of ($0.8187) per share and revenue of $2.35 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 12:30 PM ET.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). On average, analysts expect Pharvaris to post ($3.12) EPS for the current fiscal year and ($3.01) EPS for the next fiscal year.

Pharvaris Trading Down 2.2%

Pharvaris stock traded down $0.77 during trading hours on Wednesday, reaching $34.01. 29,833 shares of the stock were exchanged, compared to its average volume of 448,997. The stock has a 50 day moving average of $33.56 and a two-hundred day moving average of $31.04. Pharvaris has a twelve month low of $21.02 and a twelve month high of $43.25. The company has a market cap of $2.22 billion, a P/E ratio of -11.23 and a beta of -2.48.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on PHVS. HSBC raised Pharvaris to an “overweight” rating in a research note on Thursday, August 13th. New Street Research set a $60.00 price target on Pharvaris in a research report on Friday, August 14th. Citigroup reissued a “market outperform” rating on shares of Pharvaris in a report on Wednesday, September 9th. Wells Fargo & Company upped their price objective on shares of Pharvaris from $55.00 to $65.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 9th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 target price on shares of Pharvaris in a research report on Monday, September 14th. Fourteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $59.53.

Insider Buying and Selling

In other Pharvaris news, President Peng Lu sold 100,000 shares of the company’s stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $35.00, for a total value of $3,500,000.00. Following the completion of the sale, the president owned 64,953 shares in the company, valued at $2,273,355. This represents a 60.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Anne Lesage sold 30,000 shares of Pharvaris stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $38.30, for a total transaction of $1,149,000.00. Following the sale, the insider owned 56,450 shares in the company, valued at approximately $2,162,035. The trade was a 34.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 513,102 shares of company stock worth $18,643,666 over the last 90 days.

Pharvaris Company Profile

Pharvaris N.V. (NASDAQ: PHVS) is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder that causes recurrent episodes of swelling. The company was founded in 2015 by individuals with experience in HAE drug development and aims to provide convenient, non-injectable treatment options for patients.

Pharvaris’ lead investigational product is deucrictibant, an oral bradykinin B2 receptor antagonist designed for use both as an on-demand treatment for HAE attacks and as a preventive therapy.